Literature DB >> 7017165

Identification of an Epstein-Barr virus nuclear antigen by fluoroimmunoelectrophoresis and radioimmunoelectrophoresis.

B C Strnad, T C Schuster, R F Hopkins, R H Neubauer, H Rabin.   

Abstract

A 65,000-dalton (65K) antigen found in Raji cells by fluoroimmunoelectrophoresis and radioimmunoelectrophoresis has been identified as an Epstein-Barr virus nuclear antigen (EBNA). This identification is based on the following evidence. The 65K antigen is detected in Raji cells but not in three Epstein-Barr virus (-) human B cell lines. It is not detected with EBNA (-) sera. The 65K antigen is found predominantly in the nucleus and co-elutes with EBNA during partial purification by DNA-Sepharose and Blue Dextran-Sepharose chromatography. Finally, the partially purified 65K antigen is an effective absorbant of EBNA antibody as measured in an anticomplement immunofluorescence assay. Antigens with molecular weights of 72, 70, and 73K have been detected in B95-8, P3HR-1, and Namalwa cells, respectively. These antigens are the likely homologues of the 65K Raji EBNA. In addition, an Epstein-Barr virus-associated, 81K DNA-binding antigen has been detected in both B95-8 and Raji cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7017165      PMCID: PMC171239     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  An improved quantitative micro-complement fixation test.

Authors:  M Cikes
Journal:  J Immunol Methods       Date:  1975       Impact factor: 2.303

2.  Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus.

Authors:  M Dolyniuk; E Wolff; E Kieff
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

3.  Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid.

Authors:  W C Summers; G Klein
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

4.  Heterogeneity of Epstein-Barr virus originating from P3HR-1 cells. I. Studies on EBNA induction.

Authors:  K O Fresen; B Merkt; G W Bornkamm; H Hausen
Journal:  Int J Cancer       Date:  1977-03-15       Impact factor: 7.396

5.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

6.  Rapid purification of lactate dehydrogenase from rat liver and hepatoma: a new approach.

Authors:  L D Ryan; C S Vestling
Journal:  Arch Biochem Biophys       Date:  1974-01       Impact factor: 4.013

7.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

8.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

9.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

10.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728

View more
  38 in total

1.  Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines.

Authors:  J Finke; M Rowe; B Kallin; I Ernberg; A Rosén; J Dillner; G Klein
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites.

Authors:  C H Jones; S D Hayward; D R Rawlins
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

3.  Induction of Epstein-Barr virus nuclear antigens.

Authors:  D J Moss; T B Sculley; J H Pope
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

4.  Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells.

Authors:  A B Rickinson; L S Young; M Rowe
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

5.  Purification of Epstein-Barr virus DNA polymerase from P3HR-1 cells.

Authors:  B Kallin; L Sternås; A K Saemundssen; J Luka; H Jörnvall; B Eriksson; P Z Tao; M T Nilsson; G Klein
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

6.  Expression of a second Epstein-Barr virus-determined nuclear antigen in mouse cells after gene transfer with a cloned fragment of the viral genome.

Authors:  L Rymo; G Klein; A Ricksten
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

7.  Characterization of a major protein with a molecular weight of 160,000 associated with the viral capsid of Epstein-Barr virus.

Authors:  B Vroman; J Luka; M Rodriguez; G R Pearson
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

8.  Constitutive expression of Epstein-Barr virus-encoded RNAs and nuclear antigen during latency and after induction of Epstein-Barr virus replication.

Authors:  R Weigel; D K Fischer; L Heston; G Miller
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

9.  Identification of Epstein-Barr nuclear antigen polypeptide in mouse and monkey cells after gene transfer with a cloned 2.9-kilobase-pair subfragment of the genome.

Authors:  D K Fischer; M F Robert; D Shedd; W P Summers; J E Robinson; J Wolak; J E Stefano; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

10.  Carboxyl-terminal domain of the Epstein-Barr virus nuclear antigen is highly immunogenic in man.

Authors:  G Milman; A L Scott; M S Cho; S C Hartman; D K Ades; G S Hayward; P F Ki; J T August; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.